Epigenetic-focused CRISPR/Cas9 screen identifies (absent, small, or homeotic)2-like protein (ASH2L) as a regulator of glioblastoma cell survival CONCLUSION: Together, we suggest that targeting ASH2L could serve as a new therapeutic opportunity for glioblastoma. Video … ← Interrater agreement of multi-professional case review as reference standard for specialist palliative care need: a mixed-methods study The meaning of ubiquitylation of the DSL ligand Delta for the development of Drosophila →